Citicoline

Evidence Fact Sheet

CDP-Choline

Citicoline (CDP-choline / Cognizin) is a choline-donating phospholipid precursor studied for cognition, attention and neural support. Human evidence spans dementia meta-analyses and healthy-adult RCTs (250-500 mg/day) plus honest negatives in acute stroke and glaucoma. Sold as a supplement (US NDI / EU food supplement); no FDA/EFSA authorized claim.

Also known as: CDP-Choline · Cytidine-5'-diphosphocholine · Cognizin

Overview

Citicoline (cytidine-5'-diphosphocholine, branded Cognizin) is a naturally occurring intermediate in the Kennedy pathway that builds neuronal-membrane phosphatidylcholine; it also serves as a choline donor for acetylcholine synthesis and is studied for membrane preservation and cholinergic and dopaminergic neurotransmission. In healthy-adult cognition research it is typically used at 250-500 mg/day (DSLD median 250 mg/day), while gram-level dosing appears only in prescription acute-neurology settings that are a distinct use-context. In the US it is marketed as a DSHEA dietary supplement (NDI status varies by manufacturer) and in several EU member states as a food supplement; a parallel OTC/Rx drug identity exists internationally. There is no FDA or EFSA authorized health claim, and it is regulated as a prescription medicine in China and case-by-case in Brazil. This page reports research findings in studied populations and is not dosing or medical guidance.

Mechanism of Action

Kennedy pathway phospholipid synthesis precursor (phosphatidylcholine) · Choline donor for acetylcholine synthesis · Mitochondrial membrane cardiolipin support · Phospholipase A2 inhibition (membrane preservation) · Dopaminergic pathway modulation (research context)

Body systems: CNS · Vision · Mitochondrial & Cellular Energy · Mood & Stress Response · Musculoskeletal

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Citicoline is not characterized as a treatment for any disease.

Cognition / Dementia Symptoms

Meta-analysis supported

SMD 0.56 (95% CI 0.37-0.75)pooled cognition · lower bound
SMD 1.57 (95% CI 0.77-2.37)pooled cognition · upper bound
7 studiesincluded (6 pooled)

A systematic review and meta-analysis pooling citicoline trials found an overall improvement in cognitive status, with standardized mean differences ranging from 0.56 to 1.57 across sensitivity analyses. The authors flag an important caveat: overall study quality was poor with significant risk of bias favoring the intervention, so confidence in the magnitude is limited.

Reported effect: Pooled standardized mean differences ranging from 0.56 (95% CI: 0.37-0.75) to 1.57 (95% CI: 0.77-2.37); seven studies included, six in meta-analysis; overall quality of studies was poor with significant risk of bias in favor of the intervention

“Overall, citicoline improved cognitive status, with pooled standardized mean differences ranging from 0.56 (95% CI: 0.37-0.75) to 1.57 (95% CI: 0.77-2.37) in different sensitivity analyses.”

Source: PMID 36678257 · Bonvicini 2023 · Nutrients

Memory in Healthy Older Adults

RCT supported

3.78 vs 0.72composite memory · P=0.0052
0.15 vs 0.06episodic memory · P=0.0025
100participants · 12 wk

In a 12-week randomized, double-blind, placebo-controlled trial of 100 healthy older adults taking 500 mg/day citicoline, composite memory (a secondary outcome from four memory tests) improved significantly more than placebo (mean 3.78 vs 0.72, P=0.0052), and episodic memory on the Paired Associate test also improved (0.15 vs 0.06, P=0.0025).

Reported effect: Composite memory mean 3.78 (citicoline) vs 0.72 (placebo), P=0.0052; episodic memory 0.15 vs 0.06, P=0.0025; n=100 (49 citicoline, 51 placebo), 500 mg/day, 12 weeks

“Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052).”

Source: PMID 33978188 · Nakazaki 2021 · J Nutr

Attention / Psychomotor Speed

RCT supported

p = 0.02improved attention
p = 0.03psychomotor speed
75adolescent males

In a randomized controlled trial of 75 healthy adolescent males given 250 or 500 mg citicoline, those receiving citicoline showed improved attention (p=0.02) and increased psychomotor speed (p=0.03) versus placebo, with a higher weight-adjusted dose predicting greater accuracy and decreased impulsivity.

Reported effect: Improved attention (p=0.02) and increased psychomotor speed (p=0.03) vs placebo; n=75 (51 citicoline, 24 placebo); 250 or 500 mg

“Individuals receiving citicoline exhibited improved attention ( p = 0.02) and increased psychomotor speed ( p = 0.03) compared with those receiving placebo.”

Source: PMID 26179181 · McGlade 2019 · J Atten Disord

Acute Ischaemic Stroke Recovery

Null / no benefit RCT supported

OR 1.03 (95% CI 0.86-1.25)global recovery · p=0.364
2298patients randomized

The large ICTUS trial randomized 2,298 acute ischaemic stroke patients to citicoline or placebo and found global recovery was similar in both groups (odds ratio 1.03, 95% CI 0.86-1.25; p=0.364). The authors concluded citicoline is not efficacious for moderate-to-severe acute ischaemic stroke under the trial's conditions. Note this gram-level acute-neurology setting is a distinct prescription use-context, not the supplement dose range.

Reported effect: Global recovery similar in both groups: odds ratio 1.03 (95% CI 0.86-1.25), p=0.364; n=2298 (1148 citicoline, 1150 placebo); not efficacious

“Global recovery was similar in both groups (odds ratio 1·03, 95% CI 0·86-1·25; p=0·364).”

Source: PMID 22691567 · Dávalos 2012 · Lancet

Glaucoma / Visual Field

Null / no benefit Meta-analysis supported

no significant differencesIOP / MD 24-2 / RNFL / PERG
10 studies424 patients

A systematic review of 10 studies (424 patients) found no significant differences in intraocular pressure, visual field mean defect, retinal nerve fiber layer, or PERG amplitude between citicoline and control groups, concluding there is insufficient evidence that citicoline slows glaucoma progression. (Eye-drop research is a separate delivery route from oral supplementation.)

Reported effect: No significant differences in IOP, MD 24-2, RNFL, or PERG P50-N95 amplitude between citicoline and control; 10 studies, 424 patients; lack of sufficient evidence

“There were no significant differences in the IOP, MD 24-2, RNFL, or PERG P50-N95 amplitude between patients receiving citicoline and the control group.”

Source: PMID 37768938 · Prinz 2023 · PLoS One

Dosage (research context · not a recommendation)

250-500 mg/day in healthy-adult cognition RCTs (Cognizin); DSLD median 250 mg/day (range 120-600 mg). Educational reference, not a dosing recommendation. Rx-context acute-injury studies used 1000-2000 mg/day (prescription setting, distinct use-context, not supplement-relevant).

Regulatory Status · 4 Markets

US · FDA: Marketed as a DSHEA dietary supplement (Cognizin and others) — NDI / self-determined status varies by manufacturer (no single accepted NDIN confirmed) · 0 GRAS GRN · 0 FDA authorized health claim · note a parallel OTC/Rx drug identity exists internationally (ATC N06BX06) · DSLD ~46 products
EU · EFSA: Sold as a food supplement in several EU member states (Italy, Spain, etc.) · 0 EFSA authorized health claim
CN · China: Citicoline sodium is a prescription drug in China (injectable, acute neuro indications); oral supplement form not approved as novel/health-food ingredient.
BR · ANVISA: Regulated principally as a prescription medicine in Brazil · dietary-supplement pathway requires case-by-case evaluation · no IN 28/2018 Anexo V alegação funcional

Safety

Generally well tolerated in trials; uncommon headache/insomnia/GI discomfort (<5%). High doses may disturb sleep — research suggests morning dosing. Theoretical levodopa potentiation and AChE-inhibitor additive effect; disclose concomitant use to a clinician. No adequate pregnancy/lactation data.

Goals: cognitive-support

Lifestyles: senior-60-plus

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

PMID 36678257 · Bonvicini 2023 · Nutrients — Cognition / Dementia Symptoms
PMID 33978188 · Nakazaki 2021 · J Nutr — Memory in Healthy Older Adults
PMID 26179181 · McGlade 2019 · J Atten Disord — Attention / Psychomotor Speed
PMID 22691567 · Dávalos 2012 · Lancet — Acute Ischaemic Stroke Recovery
PMID 37768938 · Prinz 2023 · PLoS One — Glaucoma / Visual Field

Frequently Asked Questions

1. What is citicoline and how is it thought to work?

Citicoline (cytidine-5'-diphosphocholine, or CDP-choline; branded Cognizin) is a naturally occurring intermediate in the Kennedy pathway that the body uses to build neuronal-membrane phosphatidylcholine. It also acts as a choline donor for acetylcholine synthesis and is studied in the context of membrane preservation and cholinergic and dopaminergic neurotransmission. This is mechanistic background, not a claim of disease treatment.

2. Does the evidence include honest negatives?

Yes. The large ICTUS stroke trial (Dávalos 2012) found global recovery was similar between citicoline and placebo (odds ratio 1.03, p=0.364) and concluded it was not efficacious in that prescription acute-neurology setting. Separately, a systematic review of glaucoma studies (Prinz 2023) found no significant differences in intraocular pressure or visual field measures and insufficient evidence that citicoline slows glaucoma progression. Even the cognition meta-analysis (Bonvicini 2023) flagged poor study quality and risk of bias.

3. Is citicoline an approved treatment or health claim?

No. In the US it is marketed as a DSHEA dietary supplement (NDI status varies by manufacturer) and in several EU member states as a food supplement, with no FDA or EFSA authorized health claim. It is regulated as a prescription medicine in China and evaluated case-by-case in Brazil. This page reports research findings in studied populations and is not medical or dosing guidance.

Last evidence review: 2026-06-13

← Evidence library